← SynDRA
TOZADENANT
SynDRA canonical compound SYN0031607 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
|---|
| Primary target(s) | ADORA2A |
|---|
| Mechanism of action | Adenosine receptor antagonist |
|---|
All known targets
Mechanisms of action (all sources)
- Adenosine receptor antagonist
- ADORA2A ANTAGONIST
- Adenosine A2a receptor antagonist
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ADORA1
- ADORA2B
- ADORA3
- CYP1A2
- CYP2C19
- CYP2C9
- CYP2D6
- HDAC6
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Cross-references
Synonyms
- A-2A (3)
- A2A-(3)
- RO-4494351
- RO-4494351-000
- RO-4494351-002
- RO-4494351000
- RO4494351
- RO4494351-000
- RO4494351-002
- SYN-115
- SYN115
- Ro-2
- A2a receptor antagonists (Parkinson's disease), Synosia/Roche
- Adenosine A2a receptor antagonists (Parkinson's disease), Synosia/Roche
- D9K857J81I
- Ro-4494351000
- Ro-4494351-002
- Ro-4494351-000
- tozadenantum
- RefChem:190521
- Tozadenant [USAN]
- MFCD21642026
- Tozadenant (USAN)
- Tozadenant [USAN:INN]
- UNII-D9K857J81I
- C19H26N4O4S
- TOZADENANT [INN]
- TOZADENANT [WHO-DD]
- GTPL5611
- orb1299923
- SCHEMBL1628246
- SCHEMBL29361846
- CHEBI:177494
- XNBRWUQWSKXMPW-UHFFFAOYSA-N
- GLXC-90401
- BDBM50011294
- EX-A11088
- AKOS016005201
Look up TOZADENANT in the interactive SynDRA portal →